mazdutide
Peptideexperimental
Clinical trial activity
29 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
20
Phase 3
9
Phase 4
0
Earliest trial started Dec 5, 2016 (NCT02972645)
Timeline
Indications
Studied for
- Alcoholism · Phase 2
- Body Weight · Phase 1
- Cognitive Dysfunction · Phase 3
- Dementia · Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Fatty Liver · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 2
- Heart Failure, Diastolic · Phase 2
- Kidney Failure, Chronic · Phase 1
- Obesity · Phase 3
- Overweight · Phase 3
- Polycystic Ovary Syndrome · Phase 1/Phase 2
- Sleep Apnea Syndromes · Phase 3
Mechanism of action
- GlucagonAGONIST
GCG agonist
GLP1R agonist
- Glucagon receptorAGONIST
GCGR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095358 ↗
Also known as
- ly3305677
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07255209 | Phase 3 | Dec 1, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07135141 | N/A | Sep 30, 2025 | Capital Medical University |
| NCT07083154 | Phase 3 | Sep 27, 2025 | Central South University, Changzhou No.2 People's Hospital, Fudan University, Jiao Tong University, Nanjing Medical University, Nanjing University |
| NCT06937749 | Phase 2 | Jul 1, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07000955 | Phase 1/Phase 2 (Phase 2) | Jun 17, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06931028 | Phase 3 | Jun 12, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06884293 | Phase 3 | May 9, 2025 | Innovent Biologics (Suzhou) Co. Ltd., Peking University |
| NCT06862908 | Phase 2 | Mar 15, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06817356 | Phase 2 | Feb 28, 2025 | Eli Lilly |
| NCT06519656 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2024 | Fudan University |
| NCT06536023 | Phase 1 | Aug 30, 2024 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06184568 | Phase 3 | Jan 31, 2024 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06164873 | Phase 3 | Dec 31, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06124807 | Phase 2 | Nov 17, 2023 | Eli Lilly |
| NCT06143956 | Phase 2 | Nov 17, 2023 | Eli Lilly |
| NCT05793450 | Phase 1 | May 5, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05815680 | Phase 1 | Apr 6, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05628311 | Phase 3 | Nov 23, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05606913 | Phase 3 | Nov 23, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05607680 | Phase 3 | Nov 19, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 20 of 29 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 19 | 19 | 3 | 2020 |
| Eli Lilly | For profit | 7 | 7 | 2 | 2016 |
| Fudan University | Academic/Hospital | 2 | 1 | 2 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Changzhou No.2 People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nanchang University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
11 organizations
Page 1 / 1